vs
Side-by-side financial comparison of Innoviz Technologies Ltd. (INVZ) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Innoviz Technologies Ltd. is the larger business by last-quarter revenue ($15.3M vs $12.6M, roughly 1.2× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -100.9%, a 351.6% gap on every dollar of revenue.
Luminar Technologies Inc. was an American technology company that developed vision-based lidar and machine perception technologies, primarily for self-driving cars. The company's headquarters and main research and development facilities were in Orlando, Florida; a second major office was located in Palo Alto, California.
INVZ vs SPRO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.3M | $12.6M |
| Net Profit | $-15.4M | $31.5M |
| Gross Margin | 15.0% | — |
| Operating Margin | -103.4% | — |
| Net Margin | -100.9% | 250.7% |
| Revenue YoY | — | 24080.8% |
| Net Profit YoY | — | 250.9% |
| EPS (diluted) | $-0.08 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.6M | ||
| Q3 25 | $15.3M | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0K | ||
| Q4 24 | — | $52.0K | ||
| Q3 24 | — | $65.0K | ||
| Q2 24 | — | $114.0K | ||
| Q1 24 | — | $140.0K |
| Q4 25 | — | $31.5M | ||
| Q3 25 | $-15.4M | $-7.4M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-13.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-17.1M | ||
| Q2 24 | — | $-17.9M | ||
| Q1 24 | — | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -103.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | — | 250.7% | ||
| Q3 25 | -100.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -115550.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -26380.0% | ||
| Q2 24 | — | -15668.4% | ||
| Q1 24 | — | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | $-0.08 | $-0.13 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.25 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.32 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.3M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $89.7M | $59.0M |
| Total Assets | $151.1M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.3M | ||
| Q3 25 | $17.3M | $48.6M | ||
| Q2 25 | — | $31.2M | ||
| Q1 25 | — | $48.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | — | $63.5M | ||
| Q1 24 | — | $82.3M |
| Q4 25 | — | $59.0M | ||
| Q3 25 | $89.7M | $26.5M | ||
| Q2 25 | — | $32.8M | ||
| Q1 25 | — | $33.8M | ||
| Q4 24 | — | $46.1M | ||
| Q3 24 | — | $65.5M | ||
| Q2 24 | — | $80.5M | ||
| Q1 24 | — | $96.2M |
| Q4 25 | — | $68.9M | ||
| Q3 25 | $151.1M | $54.2M | ||
| Q2 25 | — | $62.1M | ||
| Q1 25 | — | $77.7M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | — | $135.2M | ||
| Q2 24 | — | $149.9M | ||
| Q1 24 | — | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.7M | $-8.4M |
| Free Cash FlowOCF − Capex | $-14.0M | — |
| FCF MarginFCF / Revenue | -91.7% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $-13.7M | $17.4M | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $-23.4M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | — | $-18.7M | ||
| Q1 24 | — | $5.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-14.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -91.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
